Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm rooted in Cambridge, Massachusetts, has recently made significant strides in its mission to develop innovative small-molecule therapeutics aimed at combating depression, anxiety, and addiction disorders. On January 14, 2025, the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439, an accomplishment that underscores the company s commitment to its research and development ambitions. This patent, en
Enveric Biosciences Charts Ambitious Course Amidst Market Challenges with New Patent for Neurotherapeutics
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Sources for this article: Based on Enveric Biosciences Inc ’s official statement and Supply Chain Analysis by CSIMarket.com
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments